Clearmind Announces Initiation of CMND-100
Manufacturing Program to Address its Upcoming Clinical
VANCOUVER, Canada -- November 23, 2022 --
InvestorsHub NewsWire -- Clearmind Medicine Inc. (Nasdaq:
CMND), (FSE: CWY) ("Clearmind" or the "Company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major undertreated health problems, today announced the
initiation of clinical batches of production of its novel
psychedelic-derived drug candidate, the MEAI- based molecule-
The produced batches will be used in the
Company's upcoming first in human (FIH) clinical trial evaluating
the proprietary drug candidate compound CMND-100 for the treatment
of Alcohol Use Disorder (AUD).
Following MEAI's synthesis development process,
the compound is being produced under GMP (Good Manufacturing
Process) conditions to comply with FDA requirements. The clinical
batches production is made possible due to prior successful
production of MEAI drug substance that was used in the Company's
pre- clinical studies designed to evaluate the safety of its
"Clearmind continues its progress toward FIH
clinical trial" said Dr. Adi Zuloff-Shani, Clearmind's Chief
Executive Officer. "This milestone joins other achievements we've
made in a relatively short period. Non-clinical data
generated to date, demonstrate that our MEAI- based treatment has
the potential to treat broad range of addictions and binge
behaviors such as AUD."
"Like other addictions, AUD is a chronic
relapsing brain disorder characterized by an impaired ability to
stop or control alcohol use," she added. "Alcohol abuse is the
third most-common preventable cause of death in the United States,
where almost 6% struggle with this condition. "
The Company previously announce that it
completed a highly constructive Pre-Investigational New Drug
Application ("pre-IND") meeting with the U.S. Food and Drug
Administration ("FDA") to discuss the development of
Clearmind is a psychedelic pharmaceutical
biotech company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company's intellectual portfolio currently
consists of seven patent families. The Company intends to seek
additional patents for its compounds whenever warranted and will
remain opportunistic regarding the acquisition of additional
intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on
Nasdaq under the symbol "CMND", the Canadian Securities Exchange under
the symbol "CMND" and the Frankfurt Stock Exchange under
the symbol "CWY".
information, please contact:
Telephone: (604) 260-1566
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act and other securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates"
and similar expressions or variations of such words are intended to
identify forward-looking statements. For example, the Company is
using forward-looking statements when it discusses clinical batches
production of its novel psychedelic-derived drug candidate, the
Company's upcoming FIH clinical trial, and any future
correspondence with the FDA. Forward-looking statements are not
historical facts, and are based upon management's current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management's expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company's reports filed from time to time with the Securities and
Exchange Commission ("SEC"), including, but not limited to, the
risks detailed in the Company's final prospectus (registration No.
333-265900) filed with the SEC on November 16, 2022.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.